Inovio Pharmaceuticals Inc (INO)

[IWillBeSpokenOf]

My favorite points from the Roche deal.

I stated in a previous post that I was familiar with Roche because I have had experience training on their machines in a large operation Clinical Pathology Lab. I also have a unique opportunity to learn lean processing from one of their continuous improvements specialists. All-in-all this company knows how to trim the fat off of operations, so they would only acquire a pre-clinical vaccination(s) if it had clear data to support its effects with minimal or no serious adverse events. (INO-5150) and hepatitis B (INO-1800)are pre-clinical drugs. Roche is big in pharma, but they are monsters in medical equipment, so I was excited when I saw that they took interest in Inovio's CELLECTRA® electroporation technology for delivery of the vaccines.

The best part about this is not the main vaccine that is in Phase II (VGX-3100) therapeutic HPV vaccine that generated best-in-class T-cell responses in a phase I study. Is the vaccine everyone was assuming would get (and stay may) licenses through big pharma. This leaves a huge opportunity for Inovio to either stand up on their own with the Roche backing in similar (if not further behind) vaccines, or to merge with another company and make even more cheddar!!!